NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $68.73 +1.29 (+1.91%) Closing price 04:00 PM EasternExtended Trading$67.71 -1.02 (-1.49%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Halozyme Therapeutics Stock (NASDAQ:HALO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$66.66▼$69.1850-Day Range$61.63▼$70.9352-Week Range$51.06▼$82.22Volume2.00 million shsAverage Volume1.76 million shsMarket Capitalization$8.15 billionP/E Ratio24.72Dividend YieldN/APrice Target$80.67Consensus RatingModerate Buy Company Overview Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration. The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix. This mechanism facilitates the dispersion and absorption of co-administered therapeutic agents, allowing high-volume subcutaneous injections that were previously limited to intravenous infusion. ENHANZE has been incorporated into multiple commercial partnerships, enabling pharmaceutical and biotechnology companies to develop subcutaneous formulations of existing and novel therapies. In addition to its commercial collaborations, Halozyme maintains a pipeline of investigational products that leverage its enzyme technology. The company conducts research in oncology, immunology and inflammatory diseases, exploring novel combinations and applications of rHuPH20. Halozyme’s business model combines royalty revenues from established partner products with internal development programs to drive long-term growth and innovation. Halozyme operates on a global scale, with collaborations spanning North America, Europe and Asia Pacific. The executive leadership team, led by President and Chief Executive Officer Helen I. Torley, brings extensive experience in biopharmaceutical development, regulatory affairs and commercial strategy. Through its technology platforms and strategic alliances, Halozyme continues to advance subcutaneous delivery solutions aimed at enhancing the patient experience and expanding therapeutic possibilities.AI Generated. May Contain Errors. Read More Halozyme Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreHALO MarketRank™: Halozyme Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 114th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialHalozyme Therapeutics has a consensus price target of $80.67, representing about 17.4% upside from its current price of $68.73.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth19.97% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 19.97% in the coming year, from $7.66 to $9.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 24.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 24.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.79.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.28. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 37.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Halozyme Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.45% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 10.22, which indicates bearish sentiment.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 0.87%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.55 News SentimentHalozyme Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Halozyme Therapeutics this week, compared to 8 articles on an average week.Search Interest19 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 375% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,200,842.00 in company stock.Percentage Held by Insiders2.50% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HALO Stock News HeadlinesHalozyme Therapeutics: Royalty King55 minutes ago | seekingalpha.comHalozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 18 at 9:18 AM | msn.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 19 at 1:00 AM | Brownstone Research (Ad)HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 OutlookMay 16 at 7:41 PM | finance.yahoo.comHalozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 SharesMay 14, 2026 | insidertrades.comTherapeutics stocks Q1 recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)May 13, 2026 | msn.comHalozyme Therapeutics (NASDAQ:HALO) Price Target Lowered to $93.00 at Morgan StanleyMay 13, 2026 | americanbankingnews.comHalozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSKMay 12, 2026 | insidermonkey.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $67.30 on January 1st, 2026. Since then, HALO shares have increased by 2.1% and is now trading at $68.73. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings results on Monday, May, 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm's quarterly revenue was up 42.2% compared to the same quarter last year. Read the conference call transcript. Does Halozyme Therapeutics have any subsidiaries? Halozyme Therapeutics subsidiaries include these companies: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Top institutional investors of Halozyme Therapeutics include Dimensional Fund Advisors LP (1.76%), Arrowstreet Capital Limited Partnership (1.62%), First Trust Advisors LP (1.25%) and Mizuho Markets Americas LLC (1.12%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse, James M Daly, Cortney Caudill and Cortney Caudill. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA). Company Calendar Last Earnings5/11/2026Today5/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 4 days ago, HALO's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees390Year Founded1998Price Target and Rating Average Price Target for Halozyme Therapeutics$80.67 High Price Target$95.00 Low Price Target$56.00 Potential Upside/Downside+17.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$2.78 Trailing P/E Ratio24.72 Forward P/E Ratio8.97 P/E Growth0.28Net Income$316.89 million Net Margins23.13% Pretax Margin33.37% Return on Equity187.91% Return on Assets21.92% Debt Debt-to-Equity Ratio8.81 Current Ratio2.76 Quick Ratio2.33 Sales & Book Value Annual Sales$1.40 billion Price / Sales5.84 Cash Flow$4.86 per share Price / Cash Flow14.14 Book Value$1.85 per share Price / Book37.15Miscellaneous Outstanding Shares118,610,000Free Float115,648,000Market Cap$8.15 billion OptionableOptionable Beta0.89 Social Links The 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:HALO) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
